At the time of writing, Aldeyra Therapeutics Inc [ALDX] stock is trading at $4.07, down -3.55%. An important factor to consider is whether the stock is rising or falling in short-term value. The ALDX shares have gain 11.20% over the last week, with a monthly amount glided 27.59%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, February 2024, Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. In a post published today on Yahoo Finance, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The conference will be held virtually on February 13-14, 2024.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on February 08, 2021, and set its price target to $26. On December 16, 2020, Berenberg initiated with a Buy rating and assigned a price target of $32 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $24 on October 30, 2020. BTIG Research initiated its recommendation with a Buy and recommended $29 as its price target on October 16, 2020. Alliance Global Partners started tracking with a Buy rating for this stock on September 22, 2020, and assigned it a price target of $32. In a note dated May 12, 2020, Oppenheimer initiated an Outperform rating and provided a target price of $12 on this stock.
For the past year, the stock price of Aldeyra Therapeutics Inc fluctuated between $1.42 and $11.97. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Aldeyra Therapeutics Inc [NASDAQ: ALDX] shares were valued at $4.07 at the most recent close of the market. An investor can expect a potential return of 538.82% based on the average ALDX price forecast.
Analyzing the ALDX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.33 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.94 points at the first support level, and at 3.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.25, and for the 2nd resistance point, it is at 4.42.
Aldeyra Therapeutics Inc [ALDX] reported earnings per share of -$0.14 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.24/share, meaning a difference of $0.1 and a surprise factor of 41.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.15 per share as compared to estimates of -$0.31 per share, a difference of $0.16 representing a surprise of 51.60%.
Ratios To Look Out For
It is important to note that Aldeyra Therapeutics Inc [NASDAQ:ALDX] has a current ratio of 6.67. On the other hand, the Quick Ratio is 6.67, and the Cash Ratio is 6.63.
Transactions by insiders
Recent insider trading involved PERCEPTIVE ADVISORS LLC, 10% Owner, that happened on Oct 18 when 0.31 million shares were sold. 10% Owner, PERCEPTIVE ADVISORS LLC completed a deal on Oct 16 to sell 2.45 million shares.
